Background Multiple sclerosis typically has onset in young adults and new disease activity
diminishes with age. Most clinical trials of disease-modifying therapies for multiple sclerosis …

With a rapidly aging global population and improvement of outcomes with newer multiple
sclerosis (MS)-specific disease-modifying therapies (DMTs), the epidemiology of MS has …

Background The question of whether multiple sclerosis requires life-long disease-modifying
treatments (DMTs) remains unanswered. Some studies suggest that older patients with …

Background: Paramagnetic rim lesions (PRLs) are an imaging biomarker in multiple
sclerosis (MS), associated with a more severe disease. Objectives: To determine …

Background It is not known if and when first-line disease modifying therapy (DMT) can safely
be discontinued in relapse onset multiple sclerosis (MS) patients. Objectives To investigate …

Background Strategies for sequencing disease modifying therapies (DMTs) in multiple
sclerosis (MS) patients include escalation, high efficacy early, induction, and de-escalation …

Background Multiple sclerosis (MS) patients with stable disease course might view
continued treatment as unnecessary. However, guidelines regarding treatment …

Background and Objectives Isolated value of MRI metrics in relapsing multiple sclerosis
(RMS) as a surrogate marker of response to disease-modifying treatment (DMT) and, thus …

Almost all currently licensed disease-modifying therapies (DMTs) for MS treatment require
prolonged if not lifelong administration. Yet, as people age, the immune system has …

Abstract Purpose of Review Long-term use of multiple sclerosis (MS) disease-modifying
therapies (DMTs) is standard practice to prevent accumulation of disability …